Evidence map›Paper›PMID 36644155›Full record

ArticleOncology letters2023

A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature.

Fabian De Smedt, Frédérique Dessy, Luciano Carestia, Pamela Baldin, Frank Aboubakar Nana, Philippe Clapuyt, Véronique Boon, Frédéric Amant, Mina Mhallem Gziri

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Fabian De SmedtDepartment of Obstetrics, Clinique Saint-Pierre, 1340 Ottignies, Belgium.
Frédérique DessyDepartment of Obstetrics, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
Luciano CarestiaDepartment of Pneumology, Clinique Saint-Pierre, Avenue Reine Fabiola 9, 1340 Ottignies, Belgium.
Pamela BaldinDepartment of Pathology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
Frank Aboubakar NanaDepartment of Pneumology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
Philippe ClapuytDepartment of Radiology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
Véronique BoonDepartment of Obstetrics, Clinique Saint-Pierre, 1340 Ottignies, Belgium.
Frédéric AmantDepartment of Gynecologic Oncology, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium.
Mina Mhallem GziriDepartment of Obstetrics, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
Cliniques Universitaires Saint-Luc · BEClinique Saint Pierre · BEUniversitair Ziekenhuis Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene account for 5% of non-small cell lung cancer (NSCLC) cases. ALK inhibitors have markedly improved the outcome of metastatic ALK-positive NSCLC (ALK

Indexed as

alectinibanaplastic lymphoma kinase genelung cancerpregnancy

Identifiers

PMID36644155
PMCPMC9827466
OpenAlexW4311951883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.